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Dear Editor,
We present a case of a 6-year-old boy of Polish origin who was
diagnosed with glucose-6-phosphate dehydrogenase (G6PD)
deficiency due to Seoul mutation. The patient was born prema-
turely in the 36th week of gestation. There was no history of
any hematological disorders in parental families. At birth, it was
noted that the patient presented severe hyperbilirubinemia
(19 mg/dl). Infection and serological conflict were ruled out
as possible causes of jaundice. At the age of 6 weeks, anemia of
prematurity was diagnosed, and due to a Hb concentration of
7.2 g/dl, packed red cells were transfused. During infancy, his
hemoglobin concentration approximately ranged between 9.5
and 10.5 g/dl. At the age of 2 years, the boy presented with
hemolytic crisis during a rotaviral infection. His full blood
count values were as follows: Hb 6.9 g/dl, RBC 2.3×1012/l,
MCV 92 fl, reticulocytes 4 %, PLT 436×109/l, WBC 8,464×
106/l, and bilirubin 2.0 mg/dl. Both direct and indirect antiglob-
ulin tests were negative. There was no hepato- or splenomegaly.
Hereditary spherocytosis was excluded using the eosin-5-
maleimide flow cytometry test. After receiving a packed red
cell transfusion and symptomatic treatment, his condition im-
proved. The observation period after treatment was uneventful
with hemoglobin concentration, reticulocyte count, and
bilirubin concentration all normal. At 6 years, he presented with
a succeeding severe hemolytic crisis during an upper respirato-
ry tract infection. A Hb concentration of 3.0 g/dl led to a
broader diagnostic criteria—G6PD activity was found re-
duced—1.65 IU/g Hb (norm 13.55±2.45 IU/g Hb). Genomic
DNA was then isolated using the MagNA Pure Compact
Nucleic Acid Isolation Kit I (Roche, Germany). PCR was used
to amplify the coding sequence of exons from 9 to 12 of the
glucose-6-phosphate dehydrogenase (G6PD) gene. The DNA
fragments generated by PCR amplification were purified using
the QIAquick PCR Purification (Qiagen, Germany) and direct-
ly sequenced with BigDye Terminators and the appropriate
primers using an ABI Prism 377 sequencer (Applied
Biosystems, CA, USA). The obtained mutation was then con-
firmed by restriction endonuclease digestion by DdeI
(Fermentas, Lithuania). DNA sequencing revealed a 306
Gly⟶Ser (G6PD Seoul, class 2) mutation (Fig. 1). Moreover,
the mother gene mutation carriage was proven.
Currently, the patient is in stable condition presenting with
temporary mild hemolysis during sporadic infections. His
parents were informed to avoid certain medicines and inges-
tion of fava bean products.
Although G6PD deficiency is the most common enzyme
disorder worldwide, it has rarely been reported among Poles
[1–4]. Clinical and numerous other studies of G6PD deficien-
cy demonstrate that the disorder is most prevalent in the
Mediterranean area, in Asia, and in Africa [5]. As a result of
global population movements, hemoglobin disorders are now
increasingly common in the formerly nonindigenous countries
of Northern and Western Europe [6]. As far as Poland is
concerned, we have not experienced any immigration boom;
hence, the incidence of G6PD deficiency is still low. However,
Mediterranean mutations predominate herein, and some
autochthonic mutations were also reported [3, 4].
Our patient presented with neonatal hyperbilirubinemia
and anemia that were interpreted as symptoms of prematurity.
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After his first hemolytic crisis, hereditary spherocytosis, being
a more common cause of hemolysis in Central Europe, was
excluded [7]. The ultimate and unexpected diagnosis of
glucose-6-phosphate deficiency was made after a succeeding
hemolytic crisis. Considering the rarity of this disorder in our
country, we performed a molecular analysis which revealed a
306Gly->Ser mutation known in literature as the Seoul
mutation [8]. Structures of human Δ G6PD (lack of 25 N-
terminal residues) in complex with NADP+ and glucose-6-
phosphate (G6P) have been described by Kotaka et al. [9],
PDB entries 2BH9 and 2BHL, respectively. Models of
wt and G306S mutated enzymes were built in complex with
NADP+ and G6P. To check the influence of this mutation on
the protein structure, both structures were subjected to
energy minimization using AmberFF99 force field as
implemented in SYBYLx2.0, Tripos Inc., USA. Residues
of the strand βH, to which belongs G306, interact with
helix αo and the loop between αo and βO, so main
structural changes are observed in those regions. It is
significant as the previously described mutations located
there, for example P489L and P489S, belong to class 1
[10, 11]. The G306S mutation induces changes in struc-
tural NADP+ as well as G6P sites because a fragment
neighboring both regions is affected. We observed changes
in orientation of K360, involved in the interaction with G6P,
as well as orientations of residues in F237–E239, described as
bridging from G6P site to the structural NADP+ site [9].
We speculate that the appearance of G6PD mutations,
previously found in different parts of the world in the
Polish population, corroborates that these mutations may
have arisen due to separate events, rather than being
descendants of individual ancient mutations.
Conclusion
To the best of our knowledge, this is the first case in the
available literature, describing the Seoul mutation in a patient
of Polish origin.
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